

Please amend the application as follows.

IN THE CLAIMS:

Please cancel claims 38 without prejudice.

Please add the following new claims:

- Sub
C1
-
43. (NEW) A composition comprising an isolated recombinant polypeptide comprising a contiguous span of at least 6 amino acids of SEQ ID NO:4, wherein said contiguous span includes at least one amino acid selected from the group consisting of:
- a Phe residue at position 204 of SEQ ID NO:4;
 - a Phe residue at position 295 of SEQ ID NO:4;
 - a Cys residue at position 205 of SEQ ID NO:4; and
 - a Pro residue at position 225 of SEQ ID NO:4.
44. (NEW) The composition of claim 43, wherein said contiguous span includes said Phe residue at position 204.
45. (NEW) The composition of claim 44, wherein said polypeptide comprises a contiguous span of at least 10 amino acids of SEQ ID NO:4.
46. (NEW) The composition of claim 44, wherein said polypeptide comprises a contiguous span of at least 20 amino acids of SEQ ID NO:4.
47. (NEW) The composition of claim 44, wherein said polypeptide comprises a contiguous span of at least 50 amino acids of SEQ ID NO:4.
48. (NEW) The composition of claim 44, wherein said polypeptide comprises a contiguous span of at least 100 amino acids of SEQ ID NO:4.
49. (NEW) The composition of claim 43, wherein said contiguous span includes said Phe residue at position 295.

50. (NEW) The composition of claim 49, wherein said polypeptide comprises a contiguous span of at least 10 amino acids of SEQ ID NO:4.
51. (NEW) The composition of claim 49, wherein said polypeptide comprises a contiguous span of at least 20 amino acids of SEQ ID NO:4.
52. (NEW) The composition of claim 49, wherein said polypeptide comprises a contiguous span of at least 50 amino acids of SEQ ID NO:4.
53. (NEW) The composition of claim 49, wherein said polypeptide comprises a contiguous span of at least 100 amino acids of SEQ ID NO:4.
54. (NEW) The composition of claim 43, wherein said contiguous span includes said Cys residue at position 205.
55. (NEW) The composition of claim 54, wherein said polypeptide comprises a contiguous span of at least 10 amino acids of SEQ ID NO:4.
56. (NEW) The composition of claim 54, wherein said polypeptide comprises a contiguous span of at least 20 amino acids of SEQ ID NO:4.
57. (NEW) The composition of claim 54, wherein said polypeptide comprises a contiguous span of at least 50 amino acids of SEQ ID NO:4.
58. (NEW) The composition of claim 54, wherein said polypeptide comprises a contiguous span of at least 100 amino acids of SEQ ID NO:4.
59. (NEW) The composition of claim 43, wherein said contiguous span includes said Pro residue at position 225.
60. (NEW) The composition of claim 59, wherein said polypeptide comprises a contiguous span of at least 10 amino acids of SEQ ID NO:4.

61. (NEW) The composition of claim 59, wherein said polypeptide comprises a contiguous span of at least 20 amino acids of SEQ ID NO:4.
62. (NEW) The composition of claim 59, wherein said polypeptide comprises a contiguous span of at least 50 amino acids of SEQ ID NO:4.
63. (NEW) The composition of claim 59, wherein said polypeptide comprises a contiguous span of at least 100 amino acids of SEQ ID NO:4.
64. (NEW) A composition comprising an isolated recombinant polypeptide comprising a contiguous span of at least 10 amino acids of SEQ ID NO:4, wherein said contiguous span includes a Phe residue at position 257 of SEQ ID NO:4.
65. (NEW) The composition of claim 64, wherein said polypeptide comprises a contiguous span of at least 20 amino acids of SEQ ID NO:4.
66. (NEW) The composition of claim 64, wherein said polypeptide comprises a contiguous span of at least 50 amino acids of SEQ ID NO:4.
67. (NEW) The composition of claim 64, wherein said polypeptide comprises a contiguous span of at least 100 amino acids of SEQ ID NO:4.
68. (NEW) The composition of claim 43 wherein said polypeptide comprises the amino acid sequence of SEQ ID NO:4.

REMARKS

Election of claims for prosecution:

Claims 1, 10, 15, 21, 24-28, 32, 38-42 and newly added claims 43-68 are currently pending in the present application. New claims 43-68 of restriction Group III have been elected for prosecution.